Jeffrey Meckler
About Jeffrey Meckler
Jeffrey Meckler (age 58) has served as an independent director of Travere Therapeutics since October 2014, bringing more than 30 years of life sciences experience across business development, strategic planning, and corporate finance. He is currently CEO of Indaptus Therapeutics (since August 2021) and previously held senior roles at Intec Pharma, Cocrystal Pharma, and Pfizer; he holds a B.S. and M.S. from Carnegie Mellon University and a J.D. from Fordham University School of Law .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Indaptus Therapeutics, Inc. | Chief Executive Officer | Aug 2021–present | Operating executive experience; biopharma leadership |
| Intec Pharma, Ltd. | Chief Executive Officer; Vice Chair of the Board | Apr 2017–Aug 2021 | Led company operations and governance |
| Cocrystal Pharma, Inc. | Chief Executive Officer; Director | Apr 2015–Jul 2016 | Executive and board leadership; pharma operations |
| QLT, Inc. | Director | Jun 2012–Nov 2016 | Board service at ultra-orphan ophthalmic biotech |
| The Andra Group | Managing Director | Not disclosed | Life sciences consulting leadership |
| Pfizer Inc. | Roles in Manufacturing Systems, Market Research, BD, Strategic Planning, Corporate Finance | Early career | Led acquisitions/divestitures; blue-chip training |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Children of Bellevue (non-profit) | Past President; Board Member | Not disclosed | Pediatric advocacy; community impact |
Board Governance
- Independence: The board affirmatively determined Meckler is independent under Nasdaq standards .
- Board tenure: Director since 2014; currently one of nine independent directors on a 10-member board .
- Committee assignments:
- Nominating/Corporate Governance Committee: Chair; committee led oversight of cybersecurity since 2024; met 4 times in 2024 .
- Audit Committee: Member; Audit Committee met 5 times in 2024 and identified all members (including Meckler) as “financial experts” .
- Attendance and engagement: The board held 4 meetings in 2024; all directors attended at least 75% of board and committee meetings; independent directors met in executive session at each regular meeting .
- Board leadership: Roles of CEO and Chair are separated to promote oversight and accountability .
- Board processes: Annual self-assessment conducted by external counsel (Cooley LLP), with results indicating effective fulfillment of responsibilities .
Fixed Compensation (Director)
| Component | 2024 Amount | Notes |
|---|---|---|
| Cash fees | $72,000 | Base retainer $50,000; Audit member $10,000; Nominating/Governance Chair $12,000 |
| Stock awards (RSUs) | $44,330 | Grant-date fair value |
| Option awards | $132,990 | Grant-date fair value |
| Total | $249,320 | Sum of components |
- Program structure: 2024 non-employee director policy included base retainer ($50k), committee member fees (Audit $10k; Comp $7.5k; Nominating/Gov $5k; Science $7.5k) and chair premiums (Audit $20k; Comp $15k; Nominating/Gov $12k; Science $15k); Chair of the Board premium $35k; equity grants: initial 29,250 options + 9,750 RSUs; annual 19,500 options + 6,500 RSUs .
- 2025 adjustments (context): Chair of Board cash retainer increased to $40k; Compensation Committee chair to $20k; Compensation Committee member to $10k; equity program unchanged .
- Non-employee director compensation cap: $750,000 per year (or $1,250,000 in the first year) combining cash and equity grant-date fair value .
Performance Compensation
- Non-employee directors at Travere do not receive performance-conditioned equity; director equity awards vest on time-based schedules; dividends/dividend equivalents not paid before vesting and are forfeitable .
Other Directorships & Interlocks
| Company | Status | Role | Tenure | Potential Interlock/Conflict Notes |
|---|---|---|---|---|
| Indaptus Therapeutics, Inc. | Biopharma | CEO | Aug 2021–present | Operating role; no Travere-related transactions disclosed |
| Cocrystal Pharma, Inc. | Pharma | CEO; Director | Apr 2015–Jul 2016 | Historical role |
| QLT, Inc. | Ophthalmic biotech | Director | Jun 2012–Nov 2016 | Historical role |
- Board commitment policy: Directors limited to ≤4 other public company boards (stricter limits for public-company NEOs); the board reports all directors are in compliance with commitment limits .
Expertise & Qualifications
- Deep life sciences leadership across BD, strategic planning, corporate finance; prior Pfizer transactional experience in acquisitions/divestitures .
- Legal and analytical training: J.D. (Fordham); B.S./M.S. (Carnegie Mellon), enhancing governance and compliance perspectives .
Equity Ownership
| Metric | Value | Notes |
|---|---|---|
| Total beneficial ownership (shares) | 159,000 | <1% of outstanding; includes options exercisable or vesting within 60 days |
| Ownership % of outstanding | <1% | Based on 88,757,341 shares outstanding |
| Options counted in beneficial ownership | 84,500 | Vested or vesting within 60 days included in SEC beneficial ownership rules |
| RSUs outstanding (12/31/2024) | 6,500 | Aggregate RSUs outstanding per director summary |
| Options outstanding (12/31/2024) | 104,000 | Aggregate options outstanding per director summary |
| Pledging/Hedging | Prohibited | Insider Trading Policy bans short sales, options, collars, swaps, and similar hedging/pledging activities |
| Ownership guidelines | Met | Directors must hold ≥3x annual cash retainer within five years; all directors in compliance |
Governance Assessment
- Strengths: Independent status; chairs Nominating/Governance (cybersecurity oversight); serves on Audit and is designated a financial expert; strong attendance; compliant with stock ownership guidelines; no related-party transactions disclosed involving Meckler; independent director compensation within program caps .
- Shareholder signals: 2024 say-on-pay passed with ~95% support—indicates overall investor support for pay practices and governance environment .
- Compensation governance: Use of independent consultant (Aon) with independence safeguards; committee reviewed conflicts and found none—reduces risk of advisor conflicts .
- Board process quality: Annual self-assessment via external counsel; regular executive sessions; separated chair/CEO roles—supports oversight effectiveness .
RED FLAGS: None disclosed specific to Meckler. No attendance shortfalls; no related-party transactions; hedging/pledging prohibited; director commitment compliance affirmed by the board .